Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balsalazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 1.00 |
| ▸ | NME4 | O00746 | 3/20 | 1.00 |
| ▸ | GCDH | Q92947 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | BLVRB | P30043 | 2/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balsalazide SCHEMBL138311 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL3267109 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL118300 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL7908058 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL28818120 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL134019 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL5598491 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL133200 | 0.97 | SIRT5 (0.95) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL20184744 | 0.93 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL17392780 | 0.93 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3352773-B1 | ANTIBACTERIAL AND PROTECTIVE BACTERIOPHAGE FORMULATIONS AND METHODS FOR MAKING AND USING THEM | SAN DIEGO STATE UNIV SDSU FOUNDATION DBA SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) | 2024-12-18 | — | — | EP | claimed |
| EP-3735219-B1 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF AMINOSALICYLATES | FERRING BV (NL) | 2024-10-16 | — | — | EP | claimed |
| EP-3836912-B1 | COMBINATIONS OF SUBSTITUTED BENZAMIDES AND 5-ASA AGENTS | PHARMACYL AB (SE) | 2024-05-01 | — | — | EP | claimed |
| EP-3582814-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH EXTRA-INTESTINAL MANIFESTATIONS | ARENA PHARM INC (US) | 2024-05-01 | — | — | EP | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| EP-3484483-B1 | GLYCAN COMPOSITIONS AND METHODS OF USE | KALEIDO BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260007645-A1 | APPLICATIONS FOR NICARDIPINE IN PREPARING ANTI-LUNG CANCER PRODUCTS | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12427139-B2 | Applications for nicardipine in preparing anti-lung cancer products | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20250144134-A1 | Therapeutic Composition and Methods | VISCERA LABS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-3960858-B1 | SMALL RNA MEDICAMENT FOR PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISEASES AND COMBINATION THEREOF | BEIJING BAISHIHEKANG PHARMACEUTICAL TECH BSJPHARMA CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| US-12239660-B2 | Therapeutic composition and methods | VISCERA LABS, INC. | 2025-03-04 | — | — | US | disclosed |
| CN-119470886-A | Methyl iso-salidrone test strip and application thereof in detecting methyl iso-salidrone residues | 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) | 2025-02-18 | — | — | CN | disclosed |
| CN-115666653-A | Antibody-drug conjugates | 斯皮雷亚有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4096642-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | Alterno Labs d.o.o. (SI) | 2022-12-07 | — | — | EP | disclosed |
| US-20220347306-A1 | SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-114392264-A | Pharmaceutical composition and application thereof in treating ulcerative colitis | 陕西含光生物科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239660-B2 | Therapeutic composition and methods | CETP, APOB, FABP2 | PTGS1 2964/4885PTGS2 2466/4885SIRT5 4627/4885 |
| US-20220347306-A1 | SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, TIE1, ANTXR2 | PTGS1 3474/4885PTGS2 3099/4885SIRT5 2709/4885 |
| US-20250144134-A1 | Therapeutic Composition and Methods | S100A6, FABP2, SLC10A2 | PTGS1 1624/4885PTGS2 1086/4885SIRT5 4741/4885 |
| US-20260007645-A1 | APPLICATIONS FOR NICARDIPINE IN PREPARING ANTI-LUNG CANCER PRODUCTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCND2, CCND2 | PTGS1 2265/4885PTGS2 2117/4885SIRT5 982/4885 |
| US-12427139-B2 | Applications for nicardipine in preparing anti-lung cancer products | CACNA1D, CACNA1B, KCND2 | PTGS1 2625/4885PTGS2 3014/4885SIRT5 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.